Form 4: Avidity CFO Sells Shares for Tax Obligations

Avidity Biosciences' Chief Financial Officer, Michael F. MacLean, sold 1,974 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Michael F. MacLean, Chief Financial Officer of Avidity Biosciences, Inc., reported a sale of common stock.
• On January 7, 2026, 1,974 shares of Avidity Biosciences common stock were sold at a price of $72.23 per share.
• The sale was a "sell-to-cover" transaction, mandated by the company's equity incentive plans to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 6, 2026.
• This transaction was not a discretionary trade by Mr. MacLean and was executed under a Rule 10b5-1 plan.
• Following this transaction, Mr. MacLean beneficially owns 63,832 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary 'sell-to-cover' transaction by an executive to meet tax obligations from RSU vesting. This is a neutral event with no positive or negative implications for the company's operations or stock performance.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4.

Management Comments

• This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

This is a routine insider transaction related to equity compensation and tax obligations, common across all publicly traded companies that offer RSUs or similar equity awards. It does not reflect specific industry trends for biotechnology or Avidity Biosciences.

Comparison to Industry Standards

• This type of "sell-to-cover" transaction is a standard practice for executives in many public companies across various industries, including biotechnology, to manage tax liabilities arising from equity compensation.
• It is a common mechanism for satisfying tax obligations upon RSU vesting and is not indicative of any unique performance or governance issues specific to Avidity Biosciences or the biotech sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-discretionary sale for tax purposes, not a signal of management's view on the stock.
• Employees: No direct impact beyond the general understanding of how equity compensation and tax obligations are handled for executives.

Key Dates

Recommendation

This Form 4 details a routine "sell-to-cover" transaction by the CFO to satisfy tax obligations related to RSU vesting. It is explicitly stated as non-discretionary and executed under a Rule 10b5-1 plan. Such transactions are common and do not typically signal management's sentiment about the company's future prospects or financial health. Therefore, this filing alone provides no new information to warrant a change in investment recommendation; a "hold" stance is appropriate as investors should rely on broader company fundamentals and market conditions.

Keywords

Avidity Biosciences, RNA, Form 4, Insider Trading, Stock Sale, CFO, Michael F. MacLean, Restricted Stock Units, RSU, Tax Withholding, Sell-to-Cover, Rule 10b5-1